ALANTA Trademark

Trademark Overview

On Tuesday, August 17, 2021, a trademark application was filed for ALANTA with the United States Patent and Trademark Office. The USPTO has given the ALANTA trademark a serial number of 90886589. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, September 11, 2024. This trademark is owned by Gila Therapeutics, Inc.. The ALANTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of metabolic disorders
alanta

General Information

Serial Number90886589
Word MarkALANTA
Filing DateTuesday, August 17, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, September 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of metabolic disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGila Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02216
Party NameGila Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02216

Trademark Events

Event DateEvent Description
Tuesday, May 24, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 18, 2022ASSIGNED TO EXAMINER
Wednesday, May 18, 2022NON-FINAL ACTION WRITTEN
Wednesday, May 18, 2022NON-FINAL ACTION E-MAILED
Wednesday, May 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 24, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 9, 2023SOU TEAS EXTENSION RECEIVED
Thursday, March 9, 2023SOU EXTENSION 1 FILED
Thursday, March 9, 2023SOU EXTENSION 1 GRANTED
Saturday, March 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Friday, August 11, 2023SOU EXTENSION 2 GRANTED
Friday, August 11, 2023SOU EXTENSION 2 FILED
Tuesday, August 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 7, 2024SOU EXTENSION 3 GRANTED
Friday, March 8, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 11, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 11, 2024SOU EXTENSION 4 FILED
Wednesday, September 11, 2024SOU EXTENSION 4 GRANTED
Thursday, March 7, 2024SOU EXTENSION 3 FILED
Thursday, March 7, 2024SOU TEAS EXTENSION RECEIVED

Related Keywords

alanta disorders metabolic treatment pharmaceuticals